Strategies for implementing long‐acting cabotegravir for PrEP in US clinics serving Black women: interim healthcare provider findings from the EBONI study
Katherine Nelson(Merck & Co., Inc., Rahway, NJ, USA (United States)), Nanlesta Pilgrim, Sara M. Andrews(RTI International), Dylan Baker(University of Connecticut), Kimberly Smith, Peter Jeffery, Annemiek de Ruiter(ViiV Healthcare (Spain)), Lisa Petty, Courtney Peasant Bonner(RTI International), Theo Hodge, Heidi Swygard, Piotr Budnik(ViiV Healthcare (United Kingdom)), Yolanda Lawson, Samantha Chang(RTI International), Alftan Dyson, Kenneth Sutton, Maggie Czarnogorski, Satish Mocherla(Legacy Community Health Services), Denise Sutherland‐Philips
Cited by 4
Related Papers
Prevalence of Kaposi's sarcoma associated herpesvirus infection measured by antibodies to recombinant capsid protein and latent immunofluorescence antigen
|The Lancet|1996|631
Earlier initiation of ART and further decline in mother-to-child HIV transmission rates, 2000–2011
|AIDS|2014|397
Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy
|AIDS|2002|359
Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons
|New England Journal of Medicine|2024|260